Brainstorm Cell Therapeutics Inc (STU:GHD)
€ 2.979 0 (0%) Market Cap: 8.70 Mil Enterprise Value: 9.34 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

Brainstorm Cell Therapeutics Inc at Sachs Associates Neuroscience Innovation Forum Transcript

Jan 12, 2020 / 06:45PM GMT
Ralph Kern
Brainstorm Cell Therapeutics Inc. - COO, Chief Medical Officer

Okay. You're on? Okay. Thank you very much. So pleasure to be here. I'm the Chief Operating Officer and Chief Medical Officer of Brainstorm Cell Therapeutics. And I'm going to give you an update on our progress. 2020 should be a very exciting year for us. We're a publicly traded company. So here's our disclosure statement. Similar to others.

What's different about Brainstorm Cell Therapeutics? Well, first of all, we have about 12 or 14 year history of developing cellular therapeutics. I think we have very strong technology platform, CMC and IP protection. We have a laser focus on neurodegenerative diseases, particularly ALS which is in Phase 3, and progressive MS, which contrary to my prior speaker, is in Phase 2. So it's a surprise to you maybe.

We have a very strong background of preclinical work across the neurodegenerative disease spectrum, including animal models of Parkinson's disease, Huntington's, and so on. The unmet medical need and the market opportunity for these diseases is huge, and I think that we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot